119 related articles for article (PubMed ID: 37549191)
1. Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats.
d'Avila JC; Carlos AS; Vieira RL; Vergueiro C; Lima AT; Silva IDS; de Figueiredo VC; Chateaubriand PHP; Moreno AM; de Castro Faria Neto HC; Estato V; Siqueira RA
Microcirculation; 2023 Oct; 30(7):e12825. PubMed ID: 37549191
[TBL] [Abstract][Full Text] [Related]
2. Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.
Yang Q; Deng L; Feng C; Wen J
PeerJ; 2024; 12():e17055. PubMed ID: 38500527
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.
Terauchi Y; Utsunomiya K; Yasui A; Seki T; Cheng G; Shiki K; Lee J
Diabetes Ther; 2019 Jun; 10(3):951-963. PubMed ID: 30912033
[TBL] [Abstract][Full Text] [Related]
5. Exercise Training Reverses Structural Microvascular Rarefaction and Improves Endothelium-Dependent Microvascular Reactivity in Rats with Diabetes.
Machado MV; Martins RL; Borges J; Antunes BR; Estato V; Vieira AB; Tibiriçá E
Metab Syndr Relat Disord; 2016 Aug; 14(6):298-304. PubMed ID: 27003580
[TBL] [Abstract][Full Text] [Related]
6. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
Luippold G; Klein T; Mark M; Grempler R
Diabetes Obes Metab; 2012 Jul; 14(7):601-7. PubMed ID: 22268612
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
Cessario J; Pierre-Louis V; Wahl J; Li Z
Pharmacol Rep; 2021 Jun; 73(3):858-867. PubMed ID: 33555600
[TBL] [Abstract][Full Text] [Related]
9. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
Hansen HH; Jelsing J; Hansen CF; Hansen G; Vrang N; Mark M; Klein T; Mayoux E
J Pharmacol Exp Ther; 2014 Sep; 350(3):657-64. PubMed ID: 24993361
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
Ni XY; Feng XJ; Wang ZH; Zhang Y; Little PJ; Cao Y; Xu SW; Tang LQ; Weng JP
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38589689
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T
Cardiovasc Diabetol; 2019 Nov; 18(1):165. PubMed ID: 31779619
[TBL] [Abstract][Full Text] [Related]
13. Effect of liraglutide on microcirculation in rat model with absolute insulin deficiency.
Ivanov AN; Lagutina DD; Saveleva MS; Popyhova EB; Stepanova TV; Savkina AA; Pylaev TE; Kuznetsova NA
Microvasc Res; 2021 Nov; 138():104206. PubMed ID: 34119534
[TBL] [Abstract][Full Text] [Related]
14. Cerebral Microvascular Dysfunction and Inflammation Are Improved by Centrally Acting Antihypertensive Drugs in Metabolic Syndrome.
Estato V; Nascimento A; Antunes B; Gomes F; Coelho L; Rangel R; Garzoni L; Daliry A; Bousquet P; Tibiriçá E
Metab Syndr Relat Disord; 2017 Feb; 15(1):26-35. PubMed ID: 27929741
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
16. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
17. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study.
Bechlioulis A; Markozannes G; Chionidi I; Liberopoulos E; Naka KK; Ntzani EE; Liatis S; Rizzo M; Rizos EC
J Diabetes Complications; 2023 Apr; 37(4):108436. PubMed ID: 36842186
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats.
Baylan U; Korn A; Emmens RW; Schalkwijk CG; Niessen HWM; Krijnen PAJ; Simsek S
Eur J Clin Invest; 2022 Sep; 52(9):e13807. PubMed ID: 35488737
[TBL] [Abstract][Full Text] [Related]
19. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
20. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy.
Herat LY; Matthews JR; Rakoczy EP; Schlaich MP; Matthews VB
Front Biosci (Landmark Ed); 2023 Apr; 28(4):83. PubMed ID: 37114550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
